| Purified thymus extracts ‐ overall survival |
| Outcome |
Random effects model |
Single intervention groups in studies with more doses/regimes tested |
| pTE |
RR 1.00, 95% CI 0.79 to 1.25, P = 0.98, I²=44% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.02, 95% CI 0.80 to 1.31, P = 0.87, I²=52% |
| Thymostimulin (subgroup) |
RR 1.07, 95% CI 0.85 to 1.35, P = 0.57, I²=35% |
not applicable |
| Thymosin fraction 5 (subgroup) |
RR 0.84, 95% CI 0.49 to 1.45, P = 0.53, I²= 48% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.95, 95% CI 0.46 to 1.95, P = 0.89, I²=69% |
| Purified thymus extracts ‐ disease‐free survival |
| pTE |
RR 0.97, 95% CI 0.82 to 1.16, P = 0.77, I²= 30% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.97, 95% CI 0.82 to 1.16, P = 0.78, I²=32% |
| Thymostimulin (subgroup) |
RR 0.93, 95% CI 0.73 to 1.19, P = 0.59, I²= 54% |
not applicable |
| Thymosin fraction 5 (subgroup) |
RR 1.06, 95% CI 0.71 to 1.60, P = 0.76, I²= 38% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.07, 95% CI 0.70 to 1.64, P = 0.48, I²=41% |
| Purified thymus extracts ‐ tumour response |
| pTE |
RR 1.07, 95% CI 0.92 to 1.25, P = 0.37, I²= 53% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 1.04, 95% CI 0.89 to 1.21, P = 0.64, I²=56% |
| Thymostimulin (subgroup) |
RR 1.25, 95% CI 0.96 to 1.62, P = 0.09, I²=66% |
not applicable |
| Thymosin fraction 5 (subgroup) |
RR 0.73, 95% CI 0.24 to 2.19, P = 0.57, I²=94% |
60 mg thymosin fraction 5 (Cohen 1979)
RR 0.81, 95% CI 0.32 to 2.07, P = 0.65, I²=92% |
| Synthetic thymic peptides ‐ overall survival |
| sTP |
RR 1.21, 95% CI 0.94 to 1.56, P = 0.14, I²=0% |
6.4 mg thymosin α1(Maio 2010) and maintenance regime (Schulof 1985)
RR 1.30, 95% CI 0.92 to 1.85, P = 0.14, I²=23% |
| Synthetic thymic peptides ‐ disease‐free survival |
| sTP |
RR 3.37, 95% CI 0.66 to 17.30, P = 0.15, I²= 37% |
6.4 mg thymosin α1 (Maio 2010) and maintenance regime (Schulof 1985)
RR 2.22, 95% CI 0.67 to 7.37, P = 0.19, I²=0% |
